PFE · News · 20260912N

Product / Drug Pipeline Progress

PFIZER INC · 2026-09-12 · Importance 38 · Surprise 42

Medicus Pharma CEO Raza Bokhari highlighted a co-development and licensing opportunity with Pfizer for a CD228-targeted antibody-drug conjugate. The collaboration includes $2 million in funding and supports Medicus Pharma’s precision-oncology strategy. Separately, Medicus is advancing its SkinJect program using a 200-microgram patch dose toward registrational studies and a potential FDA approval for Gorlin syndrome.